Ross Stephens is a biochemistry PhD graduate of Sydney University with 40 years experience in cell biology and cancer research. A large part of his career has been spent in Scandinavia, especially at the Finsen Laboratory, Copenhagen University Hospital and at the Haartman Institute, University of Helsinki. He has extensive experience in University-industry collaborations, as well as employment in the pharmaceutical industry. Back in Australia he has worked closely with industry in the oncology area, and currently leads the Biomedical Radiochemistry Laboratory at the Australian National University that has collaborative research projects with Sirtex Technology Pty Ltd, an Australian company marketing a successful internal radiation therapy for liver cancer patients. In 2013 Sirtex established a personal chair for Professor Stephens in the Department of Applied Mathematics. His most recent work is in the application of radiolabelled nanoparticle composites for in vivo imaging studies of disease processes, including sepsis. He has published 140 scientific papers and is an inventor on 9 granted and 12 pending US patents.
Research Interests: Biochemistry, Cell Biology, tumour biology, cancer diagnostics, cancer prognostics and cancer therapeutics, targeted therapeutics, nanoparticle composites for radiolabeling molecular probes, nanoparticle composites for diagnostics probes and targeted therapeutics. Publication Stats at 31.03.15, 140 publications, 4594 citations, h-index 35. Nine issued US patents.
Stephens RW, Knox KJ, Philip LA, Debono KM, Bell JL, King DW, Parish CR, Senden TJ, Tanudji MR, Winter JG, Bickley SA, Tapner MJ, Pang JH, Jones SK. The uptake of soluble and nanoparticulate imaging isotope in model liver tumours after intra-venous and intra-arterial administration. Biomaterials 2015;39:218-224.
Freeman CG, Parish CR, Knox KJ, Blackmore JL, Lobov SA, King DW, Senden TJ, Stephens RW. The accumulation of circulating histones on heparan sulfate in the capillary glycocalyx of the lungs. Biomaterials 2013;34:5670-5676.
Lobov SA, King DW, Knox KJ, Senden TJ, Stephens RW. Cationised radiolabelled nanoparticles for perfusion imaging of the lungs. Biomaterials 2013;34:1732-1738.
1. Brünner N, Stephens RW, Danø K. Control of invasion and metastasis. In “Diseases of the Breast” (2nd Edition), JR Harris (Ed) Lippincott Williams and Wilkins, Philadelphia, pp 367-375 (2000).
2. Pedersen AN, Holst-Hansen C, Frandsen TL, Nielsen BS, Stephens RW, Brünner N. The urokinase plasminogen activation system in breast cancer. In “Breast Cancer: Molecular Genetics, Pathogenesis and Therapeutics” AM Bowcock (Ed) Humana Press, Totowa (NJ), pp 325-345 (1999).
3. Brünner N, Holst-Hansen C, Pedersen AN, Pyke C, Hoyer-Hansen G, Foekens J, Stephens RW. Urokinase plasminogen activator receptor in breast cancer. In “Breast cancer: Advances in biology & therapeutics” F Calvo, M Crepin, H Magdelenat, (Eds) John Libbey Eurotext, pp 201-207 (1996).
4. Stephens RW, Vaheri A. Data summaries for plasminogen, PAI-1, PAI-2, t-PA and u-PA In “Guidebook to the Extracellular Matrix and Adhesion Proteins” TE Kreis and RD Vale, (Eds) Oxford University Press, pp 81-85 and 97-99 (1993).
5. Vaheri A, Tapiovaara H, Bizik J, Sirén V, Myöhänen H, Reisberg T, Lymboussakis A, Palolahti M, Stephens RW. Plasminogen activation on tumour cell surface. In “Metastasis: Basic research and its clinical applications” HM Rabes, PE Peters, and K Munk (Eds) Karger (Basel) vol 44, pp 127-140 (1992).
6. Danø K, Behrendt N, Lund LR, Rønne E, Pöllänen J, Salonen EM, Stephens RW, Tapiovaara H, Vaheri A. Cell Surface Plasminogen Activation. In “Cancer Metastasis”, V. Schirrmacher, R Schwartz-Albiez (Eds) Springer-Verlag, Berlin, pp 98-107 (1989).
7. Taylor TKF, Ghosh P, Bushell GR, Stephens RW. Scientific Basis for the Treatment of Intervertebral Disc Disorders In “Scientific Foundation of Orthopaedic Surgery and Traumatology”, R Owen (Ed) Heinemann Medical Books (UK) pp 387-405 (1981).